Syndevrx

About Syndevrx

A clinical-stage biotechnology company at the forefront of the emerging field of metabo-oncology. The company is dedicated to developing treatments for cancers that are sensitive to metabolic hormones, with a specific focus on patients who are overweight or obese.

The core of the company's research is the development of drugs that simultaneously target cancerous tumors and the underlying metabolic hormone dysfunction that can fuel their growth. This dual-action approach sets it apart in the oncology space. The company's lead drug candidate, evexomostat (SDX-7320), is a first-in-class MetAP2 inhibitor currently in Phase 1b/2 and Phase 2 clinical trials for metastatic breast cancer.

The business model is centered on the research and development of these novel drug candidates. By focusing on the intersection of cancer and metabolic disease, the company is targeting a significant and growing patient population. The company collaborates with a team of clinical oncologists and academic researchers to advance its drug pipeline.